DRG Epidemiology's coverage of RSV comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report both the incidence and prevalence of RSV infection for each country as well as annualized case counts projected to the national population.
DRG Epidemiology's RSV forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, and the launch of the RSV vaccine affect the epidemiology of RSV over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following RSV subpopulations:
Event Estimates of Respiratory Syncytial Virus per 1,000 Among People of All Ages in 2019 and 2039
Relative Sizes of the Contributing Factors to the Trend in Events of Respiratory Syncytial Virus Over the Next 20 Years
Analysis of the Events of Respiratory Syncytial Virus in 2019, by Age
Epidemiology Data
Methods
Diagnosed Events: Inpatients
Diagnosed Events: Outpatients
Pediatric Patient Populations, by Risk Group
Singleton Pregnancies
Gestational Age
Reference Materials
Literature Review
Studies Included in the Analysis of Respiratory Syncytial Virus
Studies Excluded from the Analysis of Respiratory Syncytial Virus
Risk/Protective Factors
Risk/Protective Factors for Respiratory Syncytial Virus
Bibliography
Alison Isherwood, M.Sc., M.Res., Ph.D.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.
